J%D(, * 1)9/*8* 0G)D) ,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre, p.122, 1980. ,
Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis, Oral and Maxillofacial Surgery Clinics of North America, vol.26, issue.2, pp.123-141, 2014. ,
DOI : 10.1016/j.coms.2014.01.001
Projection de l'incidence et de la mortalité par Cancer en France En 2010, 2011. ,
Risk factors for cancers of the oral cavity, pharynx (cavity excluded) and larynx]. Presse Médicale Paris Fr, pp.1229-1240, 1983. ,
URL : https://hal.archives-ouvertes.fr/inserm-00333191
Cancer of the larynx/hypopharynx, tobacco and alcohol: Iarc international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France), Zaragoza and Navarra (Spain), pp.483-491, 1988. ,
DOI : 10.1002/ijc.2910410403
Drogues et addictions, données essentielles. Obs Fr Drogue Toxicom, 2013. ,
Analyse de l'enquête Baromètre Santé Saint Denis: Inpes, p.56, 2010. ,
Epidemiology of Head and Neck Cancer, Surgical Oncology Clinics of North America, vol.24, issue.3, pp.379-396, 2015. ,
DOI : 10.1016/j.soc.2015.03.001
Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France???The EDiTH VI study, Journal of Clinical Virology, vol.51, issue.2, pp.100-104, 2011. ,
DOI : 10.1016/j.jcv.2011.03.003
URL : https://hal.archives-ouvertes.fr/hal-00601953
Human Papillomavirus in Oropharyngeal Cancer: The Changing Face of a Disease, Biochim Biophys Acta ,
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients, Radiotherapy and Oncology, vol.92, issue.1, pp.4-14, 2009. ,
DOI : 10.1016/j.radonc.2009.04.014
Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment, Mayo Clinic Proceedings, vol.83, issue.4, pp.489-501, 2008. ,
DOI : 10.4065/83.4.489
State-of-the-art management of locally advanced head and neck cancer, British Journal of Cancer, vol.9, issue.8, pp.1341-1348, 2005. ,
DOI : 10.1056/NEJM199301213280306
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer, New England Journal of Medicine, vol.363, issue.1, pp.24-35, 2010. ,
DOI : 10.1056/NEJMoa0912217
Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck, pp.588-594, 1998. ,
DOI : 10.1002/(sici)1097-0347(199810)20:7<588::aid-hed2>3.0.co;2-f
A rational approach to pulmonary screening in newly diagnosed head and neck cancer, Head & Neck, vol.22, issue.11, pp.990-994, 2005. ,
DOI : 10.1002/hed.20261
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, New England Journal of Medicine, vol.359, issue.11, pp.1116-1127, 2008. ,
DOI : 10.1056/NEJMoa0802656
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Histoire de la notion du cancer, Hist Sci Médicales, vol.15, pp.167-172, 1981. ,
???Field cancerization??? in oral stratified squamous epithelium. Clinical implications of multicentric origin, Cancer, vol.20, issue.5, pp.963-968, 1953. ,
DOI : 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
Increased Polysomies of Chromosomes 7 and 17 during Head and Neck Multistage Tumorigenesis, Cancer Res, vol.53, issue.12, pp.2874-2883, 1993. ,
Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications, Clin Cancer Res, vol.7, issue.6, pp.1523-1532, 2001. ,
Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. The Laryngoscope, pp.2129-2140, 2002. ,
Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma, Cancer, vol.82, issue.12, pp.1957-1965, 2015. ,
DOI : 10.1002/cncr.29303
Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract, Cancer Res, vol.53, issue.7, pp.1676-1683, 1993. ,
The molecular biology of head and neck cancer, Nature Reviews Cancer, vol.83, issue.1, pp.9-22, 2011. ,
DOI : 10.1038/nrc2982
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1, Science, vol.333, issue.6046, pp.1154-1157, 2011. ,
DOI : 10.1126/science.1206923
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma, Science, vol.333, issue.6046, pp.1157-1160, 2011. ,
DOI : 10.1126/science.1208130
Molecular profiling of head and neck squamous cell carcinoma, Head & Neck, vol.366, issue.S1, pp.1625-1638, 2016. ,
DOI : 10.1002/hed.24290
URL : http://doi.org/10.1002/hed.24290
Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.357, issue.25, pp.2552-2561, 2007. ,
DOI : 10.1056/NEJMoa073770
Lessons learned from next-generation sequencing in head and neck cancer, Head & Neck, vol.53, issue.3 Suppl 2, pp.454-463, 2013. ,
DOI : 10.1002/hed.23100
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715072
Battle Against Cancer: An Everlasting Saga of p53, International Journal of Molecular Sciences, vol.15, issue.12, pp.22109-22127, 2014. ,
DOI : 10.3390/ijms151222109
p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck, Journal of Clinical Oncology, vol.18, issue.2, pp.385-394, 2000. ,
DOI : 10.1200/JCO.2000.18.2.385
Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma, Acta Biochimica Polonica, vol.63, issue.3, pp.505-509, 2016. ,
DOI : 10.18388/abp.2015_1204
Role of the p16 tumor suppressor gene in cancer., Journal of Clinical Oncology, vol.16, issue.3, pp.1197-1206, 1998. ,
DOI : 10.1200/JCO.1998.16.3.1197
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation, European Journal of Cancer, vol.57, pp.78-86, 2016. ,
DOI : 10.1016/j.ejca.2016.01.003
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials, Annals of Oncology, vol.24, issue.11, pp.2740-2745, 2013. ,
DOI : 10.1093/annonc/mdt319
Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas, International Journal of Cancer, vol.64, issue.Suppl 1, pp.2366-2372, 2014. ,
DOI : 10.1002/ijc.28580
HPV-related oropharyngeal squamous cell carcinomas: A comparison between three diagnostic approaches, American Journal of Otolaryngology, vol.35, issue.1, pp.25-32, 2014. ,
DOI : 10.1016/j.amjoto.2013.08.007
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer, Clinical Cancer Research, vol.19, issue.5, pp.1021-1034, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2063
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck, Oral Oncology, vol.50, issue.7, pp.627-632, 2014. ,
DOI : 10.1016/j.oraloncology.2014.04.003
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN?? That Induce PD-L1 Expression in Head and Neck Cancer, Cancer Research, vol.76, issue.5, pp.1031-1043, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-2001
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma, Cancer Research, vol.73, issue.6, pp.1733-1741, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-2384
The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-264, 2012. ,
DOI : 10.1038/nrc3239
Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141, J Clin Oncol, vol.34, p.6009, 2016. ,
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012, In: ASCO Meeting, 2016. ,
Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, vol.366, issue.1, pp.2-16, 2006. ,
DOI : 10.1016/j.gene.2005.10.018
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-3167, 2000. ,
DOI : 10.1093/emboj/19.13.3159
Biomarqueurs des cancers colorectaux utiles en pratique clinique, Hépato-Gastro Oncol Dig, vol.22, issue.3, pp.217-227, 2015. ,
Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, pp.31-53, 2003. ,
DOI : 10.1016/S0014-4827(02)00098-8
EGF receptor trafficking: consequences for signaling and cancer, Trends in Cell Biology, vol.24, issue.1, pp.26-34, 2014. ,
DOI : 10.1016/j.tcb.2013.11.002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884125
RAS Interaction with PI3K: More Than Just Another Effector Pathway, Genes & Cancer, vol.2, issue.3, pp.261-274, 2011. ,
DOI : 10.1177/1947601911408079
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128635
The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells, Seminars in Cell & Developmental Biology, vol.58, pp.96-107, 2016. ,
DOI : 10.1016/j.semcdb.2016.06.011
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, Oncogene, vol.12, issue.22, pp.3227-3239, 2007. ,
DOI : 10.1074/jbc.272.47.29967
URL : https://hal.archives-ouvertes.fr/hal-00319874
The role of wild type RAS isoforms in cancer, Seminars in Cell & Developmental Biology, vol.58, pp.60-69, 2016. ,
DOI : 10.1016/j.semcdb.2016.07.012
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer, Genes, Chromosomes and Cancer, vol.113, issue.5, pp.307-312, 2011. ,
DOI : 10.1002/gcc.20854
Efficacy of cetuximab???based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta???analysis, Molecular and Clinical Oncology, vol.4, issue.6, pp.1017-1024, 2016. ,
DOI : 10.3892/mco.2016.836
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas, Oncotarget, vol.7, issue.20, pp.29780-29793, 2016. ,
DOI : 10.18632/oncotarget.8957
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ?? Cetuximab in Cervical Cancer Patients, Clinical Cancer Research, vol.21, issue.11, pp.2530-2537, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2368
La voie de signalisation PI3K/AKT/mTOR, Cancero Dig, vol.1, issue.3, pp.187-189, 2009. ,
Rôle des facteurs de transcription stat3 dans la réponse aux inhibiteurs de topoisomerase: Implication dans la résistance aux traitements de chimiothérapie, Thèse de Science -Ecole doctorale de l'Université d'Angers, pp.1-175, 2006. ,
A Role for Phospholipase C--mediated Signaling in Tumor Cell Invasion, Clin Cancer Res, vol.5, issue.8, pp.2251-2260, 1999. ,
Antigen receptor signalling: a distinctive role for the p110?? isoform of PI3K, Trends in Immunology, vol.28, issue.2, pp.80-87, 2007. ,
DOI : 10.1016/j.it.2006.12.007
Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase, Molecular and Cellular Biology, vol.21, issue.12, pp.4016-4031, 2001. ,
DOI : 10.1128/MCB.21.12.4016-4031.2001
The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas, Journal of Cancer, vol.4, issue.1, pp.66-83, 2013. ,
DOI : 10.7150/jca.5112
Current management strategy of hypopharyngeal carcinoma, Auris Nasus Larynx, vol.40, issue.1, pp.2-6, 2013. ,
DOI : 10.1016/j.anl.2011.11.009
Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus, Head & Neck, vol.91, issue.5, pp.353-362, 2001. ,
DOI : 10.1002/hed.1044
Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234, Journal of Clinical Oncology, vol.32, issue.23, pp.2486-2495, 2014. ,
DOI : 10.1200/JCO.2013.53.9163
Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer, Radiotherapy and Oncology, vol.113, issue.3, pp.310-316, 2014. ,
DOI : 10.1016/j.radonc.2014.11.032
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, The Lancet Oncology, vol.11, issue.1, pp.21-28, 2010. ,
DOI : 10.1016/S1470-2045(09)70311-0
Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group, Journal of Clinical Oncology, vol.31, issue.23, pp.312854-2860, 2013. ,
DOI : 10.1200/JCO.2012.47.7802
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer, Journal of Clinical Oncology, vol.31, issue.7, pp.845-852, 2013. ,
DOI : 10.1200/JCO.2012.43.6097
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study., Journal of Clinical Oncology, vol.10, issue.8, pp.1245-1251, 1992. ,
DOI : 10.1200/JCO.1992.10.8.1245
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Journal of Clinical Oncology, vol.33, issue.29, pp.3305-3313, 2015. ,
DOI : 10.1200/JCO.2015.62.0963
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma, Anti-Cancer Drugs, vol.23, issue.9, pp.996-1001, 2012. ,
DOI : 10.1097/CAD.0b013e32835507e5
Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis, Clinical Otolaryngology, vol.49, issue.3, pp.208-218, 2015. ,
DOI : 10.1111/coa.12348
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma, Annals of Oncology, vol.26, issue.7, pp.1476-1480, 2015. ,
DOI : 10.1093/annonc/mdv194
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Oncology, vol.33, issue.35, pp.4202-4209, 2015. ,
DOI : 10.1200/JCO.2015.61.4370
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, Clinical Cancer Research, vol.18, issue.8, pp.2336-2343, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2825
Le polymorphisme des gènes des récepteurs FcRIIIa et FcRIIa peutil constituer un biomarqueur prédictif de l'efficacité clinique du cetuximab dans les carcinomes épidermoïdes des voies aéro-digestives supérieures?, pp.1-73, 2011. ,
Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients, Clin Cancer Res, 2015. ,
DOI : 10.1158/1078-0432.ccr-15-2971
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-578, 2006. ,
DOI : 10.1056/NEJMoa053422
Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies, Oral Oncology, vol.50, issue.11, pp.1041-1048, 2014. ,
DOI : 10.1016/j.oraloncology.2014.08.005
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study, Annals of Oncology, vol.26, issue.9, pp.1941-1947, 2015. ,
DOI : 10.1093/annonc/mdv268
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer, Biol Targets Ther, vol.4, pp.173-185, 2010. ,
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection, Journal of Clinical Oncology, vol.29, issue.23, pp.680-681, 2011. ,
DOI : 10.1200/JCO.2011.35.5651
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck, Journal of Clinical Oncology, vol.23, issue.24, pp.5578-5587, 2005. ,
DOI : 10.1200/JCO.2005.07.120
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands, European Archives of Oto-Rhino-Laryngology, vol.7, issue.Suppl 3, pp.455-464, 2016. ,
DOI : 10.1007/s00405-015-3495-y
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies, European Journal of Cancer, vol.49, issue.6, pp.1161-1168, 2013. ,
DOI : 10.1016/j.ejca.2012.11.018
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study, Annals of Oncology, vol.22, issue.5, pp.1078-1087, 2011. ,
DOI : 10.1093/annonc/mdq588
Exons 19 and 21 of Epidermal Growth Factor Receptor Are Highly Conserved in Squamous Cell Cancer of the Head and Neck, International Journal of Otolaryngology, vol.1, issue.5, p.649615, 2009. ,
DOI : 10.1159/000110425
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma, European Journal of Cancer, vol.42, issue.1, pp.109-111, 2006. ,
DOI : 10.1016/j.ejca.2005.08.034
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response, BMC Research Notes, vol.7, issue.1, p.337, 2014. ,
DOI : 10.1016/j.ijrobp.2010.07.008
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma, Oral Oncology, vol.51, issue.1, pp.53-58, 2015. ,
DOI : 10.1016/j.oraloncology.2014.08.014
Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes, International Journal of Otolaryngology, vol.48, issue.16, p.848021, 2013. ,
DOI : 10.1038/sj.onc.1206705
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma, Clinical Cancer Research, vol.20, issue.11, pp.2933-2946, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2721
Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line, Int J Oncol, vol.37, issue.6, pp.1555-1563, 2010. ,
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models, British Journal of Cancer, vol.47, issue.12, pp.2887-2895, 2014. ,
DOI : 10.1038/onc.2008.245
Mechanisms of control of microRNA biogenesis, J Biochem (Tokyo), vol.148, issue.4, pp.381-392, 2010. ,
A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk, Cancer Research, vol.68, issue.20, pp.8535-8540, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-2129
A let-7 microRNA polymorphism in the KRAS 3???-UTR is prognostic in oropharyngeal cancer, Cancer Epidemiology, vol.38, issue.5, pp.591-598, 2014. ,
DOI : 10.1016/j.canep.2014.07.008
A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers, Carcinogenesis, vol.30, issue.6, pp.1003-1007, 2009. ,
DOI : 10.1093/carcin/bgp099
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Annals of Oncology, vol.25, issue.11, pp.2230-2236, 2014. ,
DOI : 10.1093/annonc/mdu367
Impact of KRAS variant rs61764370 on breast cancer morbidity, Exp Oncol, vol.37, issue.4, pp.292-294, 2015. ,
KRAS polymorphisms are associated with survival of CRC in Chinese population, Tumor Biology, vol.7, issue.4, pp.4727-4734, 2016. ,
DOI : 10.1007/s13277-015-4314-1
SLC23A2???05 (rs4987219) and KRAS???LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck, Oncology Letters, vol.7, issue.6, pp.1803-1811, 2014. ,
DOI : 10.3892/ol.2014.2029
A 3???-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis, The Lancet Oncology, vol.12, issue.4, pp.377-386, 2011. ,
DOI : 10.1016/S1470-2045(11)70044-4
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488438
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk, Cancer Research, vol.70, issue.16, pp.6509-6515, 2010. ,
DOI : 10.1158/0008-5472.CAN-10-0689
A let-7 microRNA binding site polymorphism in the KRAS 3???UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population, Journal of Cancer Research and Clinical Oncology, vol.15, issue.2, 2016. ,
DOI : 10.1186/s13045-014-0084-2
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer, Am J Cancer Res, vol.2, issue.3, pp.298-308, 2012. ,
KRAS mutation, KRAS???LCS6 polymorphism, and non-small cell lung cancer, Lung Cancer, vol.69, issue.1, pp.51-53, 2010. ,
DOI : 10.1016/j.lungcan.2009.09.008
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879467
The involvement of Kras gene 3-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets Ther, pp.1487-1496, 2014. ,
rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis, Journal of Cancer Research and Therapeutics, vol.12, issue.2, p.699, 2016. ,
DOI : 10.4103/0973-1482.147379
A Let-7 MicroRNA SNP in the KRAS 3'UTR Is Prognostic in Early-Stage Colorectal Cancer, Clinical Cancer Research, vol.17, issue.24, pp.7723-7731, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0990
Genetic modulation of the Let-7 microRNA binding to KRAS 3???-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab???irinotecan, The Pharmacogenomics Journal, vol.69, issue.5 ,
DOI : 10.1038/tpj.2010.9
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Gynecologic Oncology, vol.141, issue.2, pp.386-401, 2016. ,
DOI : 10.1016/j.ygyno.2015.04.034
A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells, International Journal of Molecular Medicine, vol.38, issue.3, pp.919-926, 2016. ,
DOI : 10.3892/ijmm.2016.2661
and colorectal cancer outcome: a systematic review and meta-analysis, Cancer Medicine, vol.339, issue.5, pp.1385-1395, 2014. ,
DOI : 10.1002/cam4.279
The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets Ther, pp.1487-1496, 2014. ,
A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy, Clinical Cancer Research, vol.20, issue.17, pp.4499-4510, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0348
Expression but Reduces let-7 Levels, Human Mutation, vol.22, issue.2, pp.208-214, 2014. ,
DOI : 10.1002/humu.22487
Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab, Cancer Immunology Research, vol.3, issue.5, pp.567-574, 2015. ,
DOI : 10.1158/2326-6066.CIR-14-0188
Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular, Journal of the Chinese Medical Association, vol.73, issue.6, pp.292-299, 2010. ,
DOI : 10.1016/S1726-4901(10)70064-2
Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial, Japanese Journal of Clinical Oncology, vol.43, issue.5, pp.524-531, 2013. ,
DOI : 10.1093/jjco/hyt034
Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution, PLoS ONE, vol.24, issue.2, p.86697, 2014. ,
DOI : 10.1371/journal.pone.0086697.t004
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort, Acta Oncologica, vol.54, issue.7, pp.1071-1075, 2015. ,
DOI : 10.1093/annonc/mdr592
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen, BMC Cancer, vol.24, issue.Suppl 7, 2016. ,
DOI : 10.1186/s12885-016-2064-0
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck, Journal of Clinical Oncology, vol.22, issue.1, pp.77-85, 2004. ,
DOI : 10.1200/JCO.2004.06.075
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck, Cancer Chemotherapy and Pharmacology, vol.16, issue.9, pp.1227-1239, 2014. ,
DOI : 10.1007/s00280-014-2459-z
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck, Oral Oncology, vol.48, issue.9, pp.887-892, 2012. ,
DOI : 10.1016/j.oraloncology.2012.03.020
Mechanisms underlying skin disorders induced by EGFR inhibitors, Molecular & Cellular Oncology, vol.150, issue.4, 2015. ,
DOI : 10.1111/j.1468-3083.2011.04324.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905346
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial, The Lancet Oncology, vol.12, issue.4, pp.333-343, 2011. ,
DOI : 10.1016/S1470-2045(11)70034-1
Introduction : KRAS LCS6 variant is a single nucleotid polymorphism in the 3'UTR of KRAS, (a Let7 microRNA binding site) and could induced an EGFR oncogenic dependance by loss of KRAS downregulation. It could thus involve a greater sensibily to EGFR-targeted therapy, The main objective is to evaluate the association between KRAS LCS6 variant and response to Cetuximab (Cx) in metastatic Head and Neck carcinoma ,